This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $1,001,029 to Immunova Therapeutics LLC to develop a novel CD4 T cell receptor (TCR)-engineered immunotherapy for the treatment of triple-negative breast cancer (TNBC). The funding will be used to generate a Good Manufacturing Practice (GMP) grade master cell bank and viral particles for this TCR-engineered T cell product, named IMT-422 or "CD4 TCR-STEM T cells". Additionally, the award will support studies to assess the pharmacokinetics, biodistribution, and toxicity of the IMT-422 product. Upon completion of these activities, Immunova Therapeutics aims to file an Investigational New Drug (IND) application to enable future clinical trials of this TNBC immunotherapy. This research aligns with the Cancer Treatment Research program's goal of advancing innovative cancer treatment approaches with the potential for significant impact on patient outcomes.
Generated 2/25/25, 4:28 AM